Evaluation of the Khorana score for prediction of venous thromboembolism in patients with multiple myeloma

Abstract

Abstract Background Guidelines recommend thromboprophylaxis for patients with multiple myeloma (MM) at high risk for venous thromboembolism (VTE). However, the optimal risk prediction model for VTE in MM remains unclear. Khorana et al developed a VTE risk score (Khorana score) in ambulatory cancer patients receiving chemotherapy. We aimed to evaluate the predictive ability of the Khorana score in patients with MM. Methods We identified patients with MM within the Veterans Affairs health care system between 2006 and 2013. The Khorana score was calculated before treatment initiation. Using logistic regression, the relationship between risk group and VTE was assessed at 3 and 6 months. We tested model discrimination using the concordance statistic. Results In the cohort of 2870 patients with MM, there were 1328 at low risk (0 points), 1521 at intermediate risk (1‐2 points), and 21 at high risk (≥3 points) for VTE by the Khorana score. The 6‐month cumulative incidence of VTE was 5.1% (95% confidence interval [CI], 4.0%‐6.4%) in low risk, 3.9% (95% CI, 3.0%‐5.0%) in intermediate risk, 4.8% (95% CI, 0.3%‐20.2%) in high risk. The Khorana score did not strongly discriminate between patients who did and did not develop VTEs at 3 or 6 months (concordance statistic, 0.58; 95% CI, 0.54‐0.63; and 0.53, 95% CI, 0.50‐0.57, respectively. Conclusions In conclusion, in this cohort of 2870 patients with MM, the Khorana score did not predict VTE. Our study supports the need to use myeloma‐specific risk models to predict VTE risk in patients with MM.

Keywords

• cancer‐associated thrombosis
• Khorana score
• multiple myeloma
• risk prediction
• venous thromboembolism